VX-445/VX-661/VX-770 fixed-dose combination granules
Sponsors
Vertex Pharmaceuticals Inc.
Conditions
Cystic Fibrosis
Phase 3
A Phase 3, Open-label Study Evaluating the Pharmacokinetics, Safety, and Tolerability of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis Subjects 12 to Less Than 24 Months of Age
CompletedCTIS2023-503230-49-00
Start: 2024-07-16End: 2025-09-01Target: 15Updated: 2025-08-19
A Phase 3 Open-label Study Evaluating the Long term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor Triple Combination Therapy in Cystic Fibrosis Subjects 2 Years and Older
CompletedCTIS2024-515606-90-00
Start: 2022-04-01End: 2026-01-14Target: 3Updated: 2025-08-19
A Phase 3 Study Evaluating the Pharmacokinetics, Safety, and Tolerability of VX 121/Tezacaftor/Deutivacaftor Triple Combination Therapy in Cystic Fibrosis Subjects 1 Through 11 Years of Age (VX21-121-105)
RecruitingCTIS2024-513754-29-00
Start: 2023-03-06Target: 15Updated: 2025-12-17
A Phase 3, Open-label Study Evaluating the Long term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis Subjects 12 Months of Age and Older
Active, not recruitingCTIS2023-509563-24-00
Start: 2025-01-08Target: 15Updated: 2025-08-19